Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • HealthTech Dialogues
    • SastaSundar...

    SastaSundar Healthbuddy, Mitsubishi Corp sign deal worth Rs 100 crore for affordable healthcare

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-27T09:45:15+05:30  |  Updated On 14 Aug 2021 11:52 AM IST

    Founder and CEO Ravi Kant Sharma added: "The partnership with Mitsubishi Corporation will help us to connect global resources with local care. It is a milestone in our journey to expand our operations in India."


    Kolkata: Mitsubishi Corporation of Japan has signed an agreement to invest Rs 100 crore in SastaSundar Healthbuddy, a digital healthcare platform with a mission to provide consistent access to affordable healthcare in a convenient manner.


    SastaSundar is supported by a network of independent pharmacies called Healthbuddies and has an integrated model of online plus offline plus logistic plus data.


    SastaSundar has also innovated personal health tech solutions to provide personalized services using technology, according to a statement issued on Monday.


    Mitsubishi's investment follows recent investments of Rs 70.49 crore by Rohto Pharmaceuticals of Japan in SastaSundar Ventures Ltd.


    "The global experience of Mitsubishi Corporation will help us to scale our business," said SastaSundar's Founder and Executive Chairman B L Mittal.


    Read Also: CK Birla Hospital for Women to invest up to Rs 1,000 cr, add 14 hospitals by end of 2025


    "Between us, there is a match of the mission of the social objective behind the business. This is a solid partnership for the future and for making the lives of millions healthy and happy," he said.


    Founder and CEO Ravi Kant Sharma added: "The partnership with Mitsubishi Corporation will help us to connect global resources with local care. It is a milestone in our journey to expand our operations in India."


    Read Also: Strides Pharma found destroying, dumping drug production documents: USFDA Investigation

    B L MittalHealthbuddyHealthcareinvestInvestmentMitsubishiMitsubishi Corporationpharmapharma companypharma newsRavi Kant SharmaRohto PharmaSastaSundarSastaSundar Ventures Ltd
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok